Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cell carcinoma, accounting for 70-80% of all kidney cancers. Histologically composed of cells with clear cytoplasm due to intracellular glycogen and lipid accumulation. Typically occurs between ages 50-70 with a male-to-female ratio of 2:1. Due to intense vascularity, it demonstrates prominent hypervascular enhancement in the arterial phase and can enhance more than the renal cortex. Strongly associated with Von Hippel-Lindau (VHL) syndrome; develops in 40% of VHL patients. Mutation of the VHL tumor suppressor gene leads to HIF-alpha pathway activation and intense angiogenesis. Treatment is based on partial or radical nephrectomy; tyrosine kinase inhibitors and immunotherapy are used in metastatic disease.
Age Range
40-80
Peak Age
64
Gender
Male predominant
Prevalence
Common
ccRCC originates from proximal tubular epithelium. The key pathogenic event is inactivation of the VHL tumor suppressor gene (chromosome 3p25). Over 90% of sporadic ccRCC cases harbor VHL gene mutation or epigenetic silencing. VHL protein normally regulates degradation of hypoxia-inducible factor alpha (HIF-α). VHL loss → HIF-α accumulation → VEGF (vascular endothelial growth factor) overexpression → intense neoangiogenesis. This intense vascularity forms the basis of hypervascular enhancement on imaging. Intracellular glycogen and lipid accumulation causes the clear cytoplasm appearance; this intracellular lipid also produces signal drop on opposed-phase MRI. The tumor frequently demonstrates necrosis, hemorrhage, and cystic degeneration, which accounts for the heterogeneous imaging findings.
A renal mass showing prominent hypervascular enhancement in arterial phase simultaneously demonstrating signal loss on opposed-phase due to intracellular lipid is nearly pathognomonic for ccRCC. This combination simultaneously reflects the tumor's intense angiogenesis (VEGF-driven) and intracellular lipid accumulation (clear cell histology), distinguishing it from other RCC subtypes.
Prominent heterogeneous hypervascular enhancement in arterial (corticomedullary) phase. Tumor density frequently exceeds renal cortex (>100 HU). Enhancement may be homogeneous (small tumors) or heterogeneous (large tumors due to necrosis/hemorrhage). Non-enhancing areas represent necrosis or cystic degeneration.
Report Sentence
Heterogeneous solid mass in the kidney demonstrating prominent hypervascular enhancement in arterial phase, enhancing more than the renal cortex, suggesting clear cell renal cell carcinoma (ccRCC) as the leading diagnosis.
Marked decrease in tumor enhancement (washout) in nephrographic phase. Areas that enhanced intensely in arterial phase show lower density than renal parenchyma in nephrographic phase. This 'early enhancement–rapid washout' pattern is highly typical for ccRCC and distinguishes it from the progressive enhancement pattern of papillary RCC.
Report Sentence
The mass demonstrates significant washout in the nephrographic phase; combined with arterial hypervascularity, this early enhancement–rapid washout pattern is consistent with clear cell RCC.
Signal loss within the tumor on opposed-phase images compared to in-phase images. This is due to intracellular lipid (glycogen and lipid) accumulation. Signal loss is usually not diffuse but focal within the tumor. India ink artifact (chemical shift artifact) may be prominent at the tumor-kidney parenchyma interface. This finding is highly specific for ccRCC as other RCC subtypes rarely contain intracellular lipid.
Report Sentence
The mass demonstrates signal loss on opposed-phase compared to in-phase sequences, consistent with intracellular lipid content; this finding strongly supports clear cell RCC.
Heterogeneous signal on T2-weighted images — generally mildly to moderately hyperintense compared to renal cortex. Hyperintense areas represent cystic/necrotic components, while hypointense areas represent hemorrhage (hemosiderin) or fibrosis. T2 signal intensity is significantly higher compared to papillary RCC. In large tumors, internal structure is more heterogeneous with necrosis, hemorrhage, and cystic degeneration foci creating a mixed signal pattern on T2.
Report Sentence
The mass shows heterogeneous, predominantly hyperintense signal on T2-weighted images with mixed signal areas consistent with necrosis and hemorrhage.
Moderate to high diffusion restriction on diffusion-weighted imaging (DWI). ADC values are generally in the 1.0-1.5 × 10⁻³ mm²/s range, lower than normal renal parenchyma. More pronounced restriction (lower ADC) is observed in high-grade tumors. Solid components show diffusion restriction while necrotic/cystic areas show facilitated diffusion. DWI is complementary to CT for detection of small lesions and solid-cystic differentiation.
Report Sentence
The solid components of the mass demonstrate high signal on DWI and low signal on ADC map, consistent with diffusion restriction.
Mildly hypodense or isodense heterogeneous soft tissue mass compared to renal parenchyma on non-contrast CT. Internal high density areas represent hemorrhage (50-70 HU), low density areas represent necrosis or cystic degeneration. Calcification is present in 10-15% of cases, typically amorphous or linear. No macroscopic fat content (differentiating from AML). Tumor margins are usually surrounded by pseudocapsule.
Report Sentence
Heterogeneous soft tissue density mass in the kidney on non-contrast CT with internal high density areas consistent with hemorrhage and low density areas consistent with necrosis.
Demonstration of prominent hypervascularity within the tumor on color/power Doppler. Chaotic vascular pattern and intratumoral arteriovenous shunt flows may be seen. Low resistance index (RI <0.7) favors malignancy. In large tumors, peripheral vascularity may predominate due to central necrosis. Tumor thrombus within the renal vein may be detected on Doppler.
Report Sentence
Color Doppler examination demonstrates prominent hypervascularity and chaotic flow pattern within the mass, consistent with malignant vascularity.
Enhancing tumor thrombus within renal vein and/or inferior vena cava (IVC) lumen — characteristic spread pattern of ccRCC. Tumor thrombus can extend from renal vein to IVC and even to the right atrium. CT shows enhancement within the thrombus (tumor neovascularity), vessel diameter increase, and luminal filling defect. Renal vein involvement occurs in 4-10% of ccRCC cases, IVC involvement in 1-4%. Right-sided tumors show more frequent IVC invasion due to short right renal vein.
Report Sentence
Enhancing tumor thrombus is seen within the renal vein lumen and should be evaluated for IVC extension; this finding is consistent with vascular spread of ccRCC.
Criteria
Predominantly solid structure, prominent hypervascular enhancement, minimal necrosis or cystic change. Usually seen in small to medium-sized (<4 cm) tumors.
Distinct Features
Homogeneous enhancement, well-defined pseudocapsule, enhancement similar to or greater than renal cortex. Best prognosis after nephrectomy.
Criteria
Predominantly cystic structure, thin or thick septa, minimal solid component. May be classified as Bosniak III-IV cystic lesion. Cystic component >50%.
Distinct Features
Better prognosis (low grade, low stage). Enhancing septa and mural nodules are malignancy criteria. Septa are typically thin to moderate thickness.
Criteria
Can develop in any RCC subtype. High-grade, aggressive histology. Defined when sarcomatoid component exceeds 5%.
Distinct Features
More aggressive enhancement, heterogeneous structure, high necrosis rate, frequent perinephric invasion, frequent renal vein thrombosis. Worst prognosis — median survival 6-12 months.
Criteria
ccRCC developing in the setting of Von Hippel-Lindau syndrome. Tends to be bilateral and multifocal. Usually diagnosed at younger age (30-40 years).
Distinct Features
May be accompanied by bilateral renal cysts and tumors, cerebellar hemangioblastoma, retinal angioma, pheochromocytoma, pancreatic cysts/NET. Requires regular follow-up and nephron-sparing surgery.
Distinguishing Feature
Papillary RCC is hypovascular and shows minimal enhancement in arterial phase (late progressive enhancement pattern); ccRCC shows prominent hypervascular enhancement and rapid washout in arterial phase. Papillary RCC is T2 hypointense, while ccRCC is T2 hyperintense.
Distinguishing Feature
Chromophobe RCC enhances more homogeneously, may show central scar with spoke-wheel pattern, and does not show opposed-phase signal drop. ccRCC shows heterogeneous enhancement, opposed-phase signal drop, and more intense neovascularity.
Distinguishing Feature
Oncocytoma is a benign tumor showing central stellate scar and spoke-wheel enhancement pattern. Does not show opposed-phase signal drop. Tends toward homogeneous enhancement. However, reliable differentiation by imaging is not always possible; biopsy may be needed.
Distinguishing Feature
AML contains macroscopic fat (<-20 HU), ccRCC does not contain macroscopic fat. On MRI, AML shows signal loss on T1 fat-sat (macroscopic fat); ccRCC shows intravoxel signal loss on opposed-phase (intracellular lipid). India ink artifact is at margins in AML, intravoxel in ccRCC.
Distinguishing Feature
Metastases are usually multiple and bilateral, while ccRCC is usually solitary. Metastases show enhancement pattern depending on primary malignancy, lacking the typical hypervascular-washout pattern of ccRCC. Clinical history (known primary malignancy) is distinguishing.
Urgency
urgentManagement
surgicalBiopsy
Not NeededFollow-up
specialist-referralBiopsy is generally not needed for ccRCC diagnosis — characteristic imaging findings (hypervascular enhancement + washout) are diagnostic. Surgical approach is the mainstay of treatment: T1a (≤4 cm) → partial nephrectomy (nephron-sparing), T1b-T2 (4-10 cm) → partial or radical nephrectomy. Radical nephrectomy with thrombectomy is required in the presence of renal vein/IVC thrombus. In metastatic disease, tyrosine kinase inhibitors (sunitinib, pazopanib), mTOR inhibitors (everolimus), and immunotherapy (nivolumab + ipilimumab) are used. 5-year survival: localized 93%, regional 71%, metastatic 14%.
Clear cell RCC is the most aggressive and most common RCC subtype. Surgical resection (partial or radical nephrectomy) is standard treatment. Tyrosine kinase inhibitors and immunotherapy are used in metastatic disease. May be associated with VHL syndrome. 5-year survival depends on stage (44-93%).